Browse EEF2

Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Phosphorylation by CSK promotes cleavage and SUMOylation-dependent nuclear translocation of the C-terminal cleavage product.
Domain PF00679 Elongation factor G C-terminus
PF03764 Elongation factor G
PF00009 Elongation factor Tu GTP binding domain
PF03144 Elongation factor Tu domain 2
Function

Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001101 response to acid chemical
GO:0002181 cytoplasmic translation
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002931 response to ischemia
GO:0003009 skeletal muscle contraction
GO:0003012 muscle system process
GO:0006414 translational elongation
GO:0006417 regulation of translation
GO:0006936 muscle contraction
GO:0006941 striated muscle contraction
GO:0006979 response to oxidative stress
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007568 aging
GO:0007584 response to nutrient
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010608 posttranscriptional regulation of gene expression
GO:0014009 glial cell proliferation
GO:0014706 striated muscle tissue development
GO:0017182 peptidyl-diphthamide metabolic process
GO:0017183 peptidyl-diphthamide biosynthetic process from peptidyl-histidine
GO:0018202 peptidyl-histidine modification
GO:0031667 response to nutrient levels
GO:0032355 response to estradiol
GO:0033273 response to vitamin
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034976 response to endoplasmic reticulum stress
GO:0035914 skeletal muscle cell differentiation
GO:0042063 gliogenesis
GO:0042542 response to hydrogen peroxide
GO:0045471 response to ethanol
GO:0045727 positive regulation of translation
GO:0050879 multicellular organismal movement
GO:0050881 musculoskeletal movement
GO:0051593 response to folic acid
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0097305 response to alcohol
GO:1990089 response to nerve growth factor
GO:1990090 cellular response to nerve growth factor stimulus
GO:1990416 cellular response to brain-derived neurotrophic factor stimulus
GO:2000765 regulation of cytoplasmic translation
GO:2000767 positive regulation of cytoplasmic translation
Molecular Function GO:0002039 p53 binding
GO:0003746 translation elongation factor activity
GO:0003779 actin binding
GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0008097 5S rRNA binding
GO:0008135 translation factor activity, RNA binding
GO:0019001 guanyl nucleotide binding
GO:0019843 rRNA binding
GO:0032561 guanyl ribonucleotide binding
GO:0043021 ribonucleoprotein complex binding
GO:0043022 ribosome binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051015 actin filament binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005840 ribosome
GO:0005844 polysome
GO:0005913 cell-cell adherens junction
GO:0016234 inclusion body
GO:0016235 aggresome
GO:0042788 polysomal ribosome
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04152 AMPK signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-1643685: Disease
R-HSA-156842: Eukaryotic Translation Elongation
R-HSA-163841: Gamma carboxylation, hypusine formation and arylsulfatase activation
R-HSA-74160: Gene Expression
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-156902: Peptide chain elongation
R-HSA-597592: Post-translational protein modification
R-HSA-8876725: Protein methylation
R-HSA-5358493: Synthesis of diphthamide-EEF2
R-HSA-72766: Translation
R-HSA-5339562: Uptake and actions of bacterial toxins
R-HSA-5336415: Uptake and function of diphtheria toxin
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EEF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EEF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.97 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EEF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3090.289
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1950.965
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3890.906
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1750.687
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0730.985
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4890.92
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0680.913
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1210.967
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2480.94
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.070.981
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2130.963
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1510.0445
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EEF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EEF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EEF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EEF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EEF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EEF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EEF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEEF2
Nameeukaryotic translation elongation factor 2
Aliases EEF-2; polypeptidyl-tRNA translocase; EF2; EF-2; Elongation factor 2
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EEF2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting EEF2.
ID Name Drug Type Targets #Targets
DB02059Adenosine-5-DiphosphoriboseSmall MoleculeEEF2, GAPDH, SIRT3, SIRT54
DB03223DiphthamideSmall MoleculeEEF21
DB04315Guanosine-5'-DiphosphateSmall MoleculeADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......36
DB08348N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDESmall MoleculeEEF2, PARP15, PARP33